Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patientsCompleted 40 mg and 80 mg TUS dose cohorts; no prolonged myelosuppression or dose-limiting toxicitiesNo dose reductions required to the standard-of-care therapy with 40 mg and 80 mg TUS dose cohortsCSRC endorsed escalation to 120 mg TUS dosingFirst patient dosed with 120 mg TUS triplet and enrollment continues SAN DIEGO and TORONTO, May 20, 2025 (GLOBE NE ...